Omega Therapeutics, Inc. (OMGA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Omega Therapeutics, Inc. (OMGA) trades at $0.1426 with AI Score 54/100 (Grade B). Omega Therapeutics, Inc. is a development-stage biopharmaceutical company focused on epigenomic programming. Market cap: $7.90M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for OMGA: OMGA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OMGA against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OMGA: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Omega Therapeutics, Inc. (OMGA) Healthcare & Pipeline Overview
Omega Therapeutics, Inc. is a biotechnology company pioneering epigenomic programming to develop novel therapeutics. Their OMEGA platform modulates gene expression for a range of diseases, positioning them in the competitive biopharmaceutical landscape with a focus on innovative approaches to drug development and personalized medicine.
What Is the Investment Thesis for OMGA?
Omega Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's OMEGA Epigenomic Programming platform offers a novel approach to drug development by targeting the epigenome. Key value drivers include the successful advancement of OEC candidates through clinical trials and the potential for strategic partnerships. The company's ability to demonstrate clinical efficacy and safety will be critical for long-term value creation. The current market capitalization of $7.90M reflects the early stage of development and inherent risks associated with biotechnology investments. Upcoming clinical trial results for OTX-2002 and other OEC candidates will serve as significant catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's high negative profit margin of -3148.9% underscores its reliance on future revenue streams from successful drug development.
Based on FMP financials and quantitative analysis
OMGA Key Highlights
Omega Therapeutics operates in the biotechnology sector, focusing on epigenomic programming.
- The company's OMEGA Epigenomic Programming platform is designed to control gene expression for therapeutic purposes.
- Key pipeline candidates include treatments for chronic liver diseases, diabetes, corneal regeneration, idiopathic pulmonary fibrosis, and various cancers.
- Omega Therapeutics is a development-stage company with no products currently on the market.
- The company's market capitalization is $0.01 billion, reflecting its early stage and high-risk profile.
Who Are OMGA's Competitors?
OMGA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CHRO Channel Therapeutics Corporation | $1.35 | +7.14% | $8.90M | 44 |
| CSCI COSCIENS Biopharma Inc. | $2.72 | +0.00% | $8.57M | 63 |
| ENTO ENTO | $2.85 | -5.00% | $13.6M | 49 |
| FRTX Fresh Tracks Therapeutics, Inc. | $0.94 | -0.53% | $5.59M | 54 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OMGA's Key Strengths?
Novel OMEGA Epigenomic Programming platform.
- Potential for personalized medicine approaches.
- Strong intellectual property protection.
- Experienced management team.
What Are OMGA's Weaknesses?
Development-stage company with no products on the market.
- High cash burn rate.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
What Could Drive OMGA Stock Higher?
Clinical trial results for OTX-2002 in cancer patients.
- Preclinical data release for OEC candidates targeting liver diseases.
- Expansion of the OMEGA platform to new therapeutic areas.
- Strategic partnerships with pharmaceutical companies.
- Regulatory approvals for OEC candidates.
What Are the Key Risks for OMGA?
Financial-distress signal — its Altman Z-Score of -4.95 sits in the distress zone (elevated bankruptcy risk).
- Clinical trial failures for OEC candidates.
- Regulatory delays or rejection of OEC candidates.
- Competition from established pharmaceutical companies.
- High cash burn rate and need for additional funding.
- Intellectual property challenges.
What Are the Growth Opportunities for OMGA?
- Expansion into New Therapeutic Areas: Omega Therapeutics has the opportunity to expand its OMEGA platform to address a broader range of diseases. By identifying new epigenetic targets and developing OEC candidates, the company can diversify its pipeline and increase its potential market reach. The market for novel therapeutics is substantial, with unmet needs in various disease areas, including oncology, immunology, and neurology. Timeline: Ongoing, with continuous research and development efforts.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with established pharmaceutical companies can provide Omega Therapeutics with access to funding, expertise, and commercialization capabilities. Collaborations can accelerate the development and commercialization of OEC candidates, increasing the company's chances of success. The pharmaceutical industry is actively seeking innovative technologies and therapies, creating opportunities for partnerships. Timeline: Ongoing, with potential partnerships at various stages of development.
- Advancement of OTX-2002: The successful development and commercialization of OTX-2002, which targets the oncogene c-Myc, represents a significant growth opportunity for Omega Therapeutics. c-Myc is implicated in various cancers, making OTX-2002 a potential blockbuster drug. Positive clinical trial results and regulatory approval could drive substantial revenue growth. Timeline: Dependent on clinical trial progress and regulatory approval.
- Development of Personalized Medicine Approaches: Omega Therapeutics' OMEGA platform has the potential to enable personalized medicine approaches by tailoring therapies to individual patients based on their epigenetic profiles. This could lead to more effective treatments and improved patient outcomes. The market for personalized medicine is growing rapidly, driven by advances in genomics and diagnostics. Timeline: Long-term, with ongoing research and development efforts.
- Expansion into International Markets: Omega Therapeutics can expand its market reach by entering international markets. This would require navigating different regulatory landscapes and establishing partnerships with local distributors. However, the potential rewards are significant, as the global market for therapeutics is vast. Timeline: Long-term, dependent on regulatory approvals and market access strategies.
What Are OMGA's Competitive Advantages?
- Proprietary OMEGA Epigenomic Programming platform.
- Patent protection for OEC candidates.
- First-mover advantage in epigenomic programming.
- Expertise in epigenetics and drug development.
What Does OMGA Do?
Omega Therapeutics, Inc., founded in 2016 and headquartered in Cambridge, Massachusetts, is a development-stage biopharmaceutical company at the forefront of epigenomic programming. The company's core technology, the OMEGA Epigenomic Programming platform, is designed to harness the power of epigenetics, the mechanism by which genes are controlled and cells differentiate. This platform aims to co-opt nature's operating system to develop novel therapeutics for a wide range of diseases. Omega Therapeutics is developing a pipeline of omega epigenomic controller (OEC) candidates. These candidates are designed to up-regulate or down-regulate the expression of specific genes to treat various conditions. One such candidate targets the up-regulation of HNF4a, a transcriptional master regulator, as a potential treatment for chronic liver diseases. Other OEC candidates are being developed to control genes linked to cell-growth inhibition in diabetes, restore corneal regeneration capacity, down-regulate the CXCL1, 2, 3, and IL-8 gene cluster, and address genes implicated in idiopathic pulmonary fibrosis. The company is also exploring treatments for hair loss by down-regulating SFRP1 and developing therapies for non-small cell lung cancer and small cell lung cancer. Additionally, Omega Therapeutics is developing OTX-2002 to down-regulate c-Myc, an oncogene. As a development-stage company, Omega Therapeutics is focused on preclinical and clinical development, with no products currently on the market. The company's success depends on the successful development and commercialization of its OEC candidates.
What Products and Services Does OMGA Offer?
- Develops epigenomic programming therapeutics.
- Utilizes the OMEGA Epigenomic Programming platform.
- Targets gene expression to treat diseases.
- Creates omega epigenomic controller (OEC) candidates.
- Focuses on chronic liver diseases, diabetes, and cancer.
- Conducts preclinical and clinical research.
- Aims to restore liver-cell function and corneal regeneration.
How Does OMGA Make Money?
- Develops and patents novel epigenomic therapies.
- Out-licenses or partners with pharmaceutical companies for commercialization.
- Generates revenue through licensing fees, milestone payments, and royalties.
- Focuses on research and development to create new OEC candidates.
What Industry Does OMGA Operate In?
Omega Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for epigenomic therapies is still nascent but holds substantial potential, driven by the increasing understanding of the role of epigenetics in disease development. The company competes with other biotechnology and pharmaceutical companies developing novel therapies for various diseases, including BIOR, CHRO, CSCI, ENTO, and FRTX. The biotechnology industry is subject to stringent regulatory requirements and lengthy clinical trial processes, which can significantly impact the timeline and cost of drug development.
Who Are OMGA's Key Customers?
- Pharmaceutical companies seeking novel therapeutics.
- Patients suffering from chronic liver diseases.
- Patients with diabetes and corneal damage.
- Patients with idiopathic pulmonary fibrosis.
- Patients with non-small cell lung cancer and small cell lung cancer.
Forward Outlook
Wall Street analysts project Omega Therapeutics, Inc. revenue of about $6.6M for fiscal 2026, with EPS near $-0.44.
Earnings Track Record
Omega Therapeutics, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 6.3% above estimates on average.
Financial Health
Omega Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -4.95 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -47.7%, showing how much profit it generates from its asset base. A current ratio of 3.35 indicates the company holds enough short-term assets to cover its near-term obligations.
Omega Therapeutics, Inc. (OMGA) Valuation Context
Valued at $7.90M, OMGA is classified as a micro-cap stock. Relative to its peer group, OMGA's quantitative score of 54/100 is roughly in line with the peer average of 56/100.
OMGA Revenue & Earnings Trend
In Q3 2024, OMGA generated $2.6M in top-line revenue, marking a sequential increase of 22.4%. The company recorded a net loss of $16.4M, with diluted EPS of $-0.30. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare.
Company Profile
Omega Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Cambridge, US. The company is led by CEO Kaan Certel. OMGA has traded publicly since 2021.
OMGA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Novel OMEGA Epigenomic Programming platform.
- Potential for personalized medicine approaches.
- Strong intellectual property protection.
- Experienced management team.
Bear Case
- Development-stage company with no products on the market.
- High cash burn rate.
- Reliance on successful clinical trial outcomes.
- Limited financial resources.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $3M | -$16M | -$0.30 |
| Q2 2024 | $2M | -$16M | -$0.30 |
| Q1 2024 | $2M | -$20M | -$0.36 |
Based on FMP financials and quantitative analysis
OMGA Latest News
No recent news available for OMGA.
OMGA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OMGA.
Price Targets
Wall Street price target analysis for OMGA.
OMGA MoonshotScore
What does this score mean?
The MoonshotScore rates OMGA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Kaan Certel
CEO
Kaan Certel serves as the CEO of Omega Therapeutics, bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in various biotech companies, with a focus on drug development and commercialization. He has a proven track record of driving innovation and building successful teams. Certel's expertise spans across multiple therapeutic areas, including oncology, immunology, and metabolic diseases. His educational background includes advanced degrees in molecular biology and business administration.
Track Record: Under Kaan Certel's leadership, Omega Therapeutics has advanced its OMEGA Epigenomic Programming platform and expanded its pipeline of OEC candidates. He has overseen the company's preclinical and clinical development programs, securing key partnerships and funding. Certel has also focused on building a strong corporate culture and attracting top talent to the company. His strategic decisions have positioned Omega Therapeutics as a leader in the field of epigenomic programming.
Common Questions About OMGA (Healthcare)
What does the AI Score mean for OMGA?
OMGA holds an AI Score of 54/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Omega Therapeutics, Inc. is a development-stage biopharmaceutical company focused on epigenomic programming. Their OMEGA platform aims to control gene expression for treating various diseases.
What does Omega Therapeutics, Inc. do?
Omega Therapeutics, Inc. is a development-stage biopharmaceutical company pioneering a new class of medicines through its OMEGA Epigenomic Programming platform. This platform is designed to control gene expression by leveraging epigenetics, the mechanism that governs cell differentiation and gene regulation.
What are the main risks for OMGA?
Omega Therapeutics faces several key risks inherent to the biotechnology industry. Clinical trial failures pose a significant risk, as the efficacy and safety of OEC candidates must be demonstrated. Regulatory hurdles and potential delays in obtaining approvals from agencies like the FDA can impact timelines and increase costs.
What are the key factors to evaluate for OMGA?
Omega Therapeutics, Inc. (OMGA) holds an AI score of 54/100 (moderate). Omega Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does OMGA data refresh on this page?
OMGA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OMGA's recent stock price performance?
Omega Therapeutics, Inc. (OMGA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel OMEGA Epigenomic Programming platform. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OMGA overvalued or undervalued right now?
Omega Therapeutics, Inc. (OMGA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research OMGA before investing?
Before investing in Omega Therapeutics, Inc. (OMGA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OMGA to a portfolio?
Key strength of Omega Therapeutics, Inc. (OMGA): Novel OMEGA Epigenomic Programming platform. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- AI analysis is pending and may provide additional insights.